Danaher Corp (DHR) exceeded third-quarter sales expectations, with a 3% year-over-year increase driven by a continued bioprocessing recovery. Despite the positive news, capital expenditures remain weak, and guidance for 2024 anticipates a decline in non-GAAP core revenue. Analysts are closely watching the fourth-quarter exit rate for bioprocessing and potential insights into 2025.
Danaher Corporation (DHR) exceeded analysts’ expectations for third-quarter revenue and earnings, fueled by strong performance in its bioprocessing business. However, the company issued a cautious outlook for 2024, predicting a decline in core revenue due to a challenging macroeconomic environment. Despite the near-term forecast, Danaher remains optimistic about the long-term growth potential of its bioprocessing segment.
Shares of Danaher Corp (DHR) dropped in early trading on Tuesday following an analyst report predicting a gradual recovery for the company starting in 2025. Stifel analyst Jacob Johnson believes Danaher’s focus on life sciences will drive high-single-digit growth in the long term, despite recent headwinds.
Danaher Corporation, a leading life sciences company, reported strong financial results for the first quarter of 2024, surpassing analyst estimates and indicating a recovery in the biotech industry. Revenue reached $5.8 billion, a 4% organic decline year-over-year but above expectations of $5.62 billion. Adjusted earnings per share (EPS) came in at $1.92, a 6.3% annual decrease but ahead of consensus estimates of $1.71 per share. Key operating segments all delivered better-than-expected results, including biotechnology, life sciences, and diagnostics.
Life sciences toolmaker Danaher (DHR) reported better-than-expected financial results for the first quarter of 2024. Despite an 18% decline in its Biotechnology division, the company’s Life Sciences and Diagnostics divisions recorded growth, resulting in a 3% overall revenue decline compared to the same period last year. The company also reported strong operating cash flow. Danaher’s competitors, such as Repligen, Bio-Rad, and Thermo Fisher Scientific, are expected to be closely watched in light of these positive results.
Danaher (NYSE: DHR) outperformed analysts’ expectations in its first quarter earnings report, posting an EPS of $1.92, $0.20 above the estimated $1.72. The company’s revenue also surpassed estimates, coming in at $5.8 billion compared to the consensus estimate of $5.62 billion. Driven by these positive results, the stock closed at $236.08, a 3.82% gain over the last three months and a 4.72% increase over the past 12 months. However, despite the strong performance, Danaher has faced some downward revisions in EPS estimates, with 11 negative revisions occurring in the past 90 days compared to only 1 positive revision. Despite this, InvestingPro maintains a positive outlook on the company’s financial health.
